Literature DB >> 330972

Specific immunotherapy with neuraminidase-modified leukemic cells: experimental and clinical trials.

J G Bekesi, J F Holland, J P Roboz.   

Abstract

The data presented establish the therapeutic effectiveness of immunotherapy with neuraminidase-treated allogeneic myeloblasts in combination with sustaining chemotherapy in patients with acute myelocytic leukemia. The in vivo and in vitro immunologic tests indicate normal immunocompetence in patients receiving immunotherapy versus control patients treated with chemotherapy alone. These findings correlate well with the improved duration of remission as the direct result of the immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 330972     DOI: 10.1016/s0025-7125(16)31283-4

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  3 in total

1.  Adjuvant specific immunotherapy in maintenance treatment of adult acute non-lymphocytic leukemia.

Authors:  H Rühl; H H Fülle; K M Koeppen; R Schwerdtfeger
Journal:  Klin Wochenschr       Date:  1981-11-02

2.  Current aspects of immunotherapy in cancer.

Authors: 
Journal:  Langenbecks Arch Chir       Date:  1981

3.  Effect of neuraminidase treatment on serum reactivity to autologous leukemic blast cells.

Authors:  M Pfreundschuh; B Dörken; W Brandeis; W Hunstein; P Wernet
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.